

Patent Assignment Abstract f Title

NOTE: Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 2

Patent #: 6264922 **Issue Dt:** 07/24/2001 **Application #:** 08948216 **Filing Dt:** 10/09/1997

Inventors: RAY W. WOOD, LAN DECASTRO, H. WILLIAM BOSCH

Title: NEBULIZED AEROSOLS CONTAINING NANOPARTICULATE DISPERSIONS

Assignment: 1

Reel/Frame: 010797/0486

Recorded: 05/05/2000

Pages: 15

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: NANOSYSTEMS, L.L.C.

Exec Dt: 10/01/1998

Assignee: ELAN CORPORATION, PLC

LINCOLN HOUSE, LINCOLN PLACE
DUBLIN 2, IRELAND

Correspondent: FOLEY & LARDNER

MICHELE M. SCHAFER
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-8696

Assignment: 2

Reel/Frame: 010797/0501

Recorded: 05/05/2000

Pages: 17

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor: ELAN CORPORATION, PLC

Exec Dt: 10/01/1998

Assignee: ELAN PHARMA INTERNATIONAL LIMITED

WIL HOUSE, SHANNON BUSINESS PARK
SHANNON, CO. CLARE, IRELAND

Correspondent: FOLEY & LARDNER

MICHELE M. SCHAFER
3000 K STREET, N.W.
SUITE 500
WASHINGTON, DC 20007-8696

Search Results as of: 02/03/2004 10:51 AM

FORM PTO-1595 (modified)

(Rev. 8-93)

RECO

05-23-2000



101364078

EET

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

5.5.00

T the Commissioner of Pat nts and Trademarks: Please record the attached original documents r copies thereof.

1. Name of conveying party(ies):

Elan Corporation, PLC



2. Name and address of receiving party(ies):

Elan Pharma International Limited
WIL House, Shannon Business Park
Shannon, Co. Clare
IRELAND

Additional conveying party(ies)

NO

3. Nature of conveyance:

ASSIGNMENT

Execution Date: October 1, 1998

Additional name(s) & address(es) attached? NO

4. Application number(s) or patent number(s):

If this is being filed together with a new application, the execution date of the application is: N/A

A. Patent Application Number(s):

08/948,216

B. Patent Number(s):

Additional numbers attached? NO

5. Name and address of party to whom correspondence concerning document should be mailed:

Michele M. Schafer
FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
P.O. Box 25696
Washington, D.C. 20007-8696

6. Total number of applications/patents involved: 1

7. Total fee (37 C.F.R. § 3.41): \$40.00

☒ Check Enclosed

Charge to deposit account

8. Deposit account number: 19-0741

05/02/2000 JMM/022 00000073 00948216

DO NOT USE THIS SPACE

01 FC1501

40.00 OP

9. Statement and signature:

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. The Commissioner is hereby authorized to charge any additional recordation fees which may be required in this matter to the above-identified deposit account.

Michele M. Schafer

May 5, 2000

Name of person signing

Signature

Date

Total number of pages including cover sheet, attachments, and document: 17

ASSIGNMENT AGREEMENT

ASSIGNMENT AGREEMENT among Elan Corporation, plc ("Elan") and Elan Pharma International Limited, a wholly-owned subsidiary of Elan ("EPI"). For consideration consisting of an amount in cash equal to the Purchase Price (as defined in the Agreement) less the sum of the amounts paid by Elan Pharmaceutical Research Corp. ("EPRC") to Elan in consideration for the assets separately conveyed plus the amounts paid by EPRC to NanoSystems I.L.C. for certain leasehold improvements, the parties hereto agree that, effective immediately after the closing of the transactions referred to in the Agreement referred to below, Elan assigns to EPI all of Elan's right, title and interest in and to all Intellectual Property included in the Acquired Assets (other than the rights to develop and commercialize a nanocrystal version of Paclitaxel) in accordance with the terms of the Asset Purchase Agreement (the "Agreement") by and among NanoSystems I.L.C., Eastman Kodak Company and Elan.

Capitalized terms not defined herein shall have the meaning ascribed to them in the Agreement.

[signature page follows]

RLV


FOLEY & LARDNER DC : 5-14-88 : 9:48AM :
US 00184 PROPELAN PMAAM

-FOLEY & LARDNER DC C: 2
1-000 P.02/02 P-000

-2-

IN WITNESS WHEREOF, the parties hereto have executed
this Assignment Agreement as of the 1st day of October, 1988.

ELAN CORPORATION, PLC

By: 
Name: Donald J. Jancy
Title: Chairman of Board
Director of Elan Corp., pl.

We hereby assume the rights, title and interest specified
above.

ELAN PHARMA INTERNATIONAL
LIMITED

By: 
Name: David Foster
Title: Director



ASSET PURCHASE AGREEMENT

by and between

**NANOSYSTEMS L.L.C.,
EASTMAN KODAK COMPANY**

and

ELAN CORPORATION, PLC

Dated as of August 21, 1998

NY11528:97445.11

PATENT

REEL: 010797 FRAME: 0504



SCHEDULES TO DISCLOSURE STATEMENT

Schedule 1.1(a)	Equipment
Schedule 1.1(b)	NanoSystems Real Property
Schedule 1.1(c)	NanoSystems Intellectual Property
Schedule 3.8	Capitalization
Schedule 3.10	Absence of Change
Schedule 4.5	Consents
Schedule 4.6(a)	Intellectual Property Infringements
Schedule 4.6(b)	Intellectual Property Restrictions
Schedule 4.8(a)	Material Contracts
Schedule 4.8(b)	Contracts: Breaches/Events
Schedule 4.8(c)	Certain Contracts
Schedule 4.9	Manufacturing Rights
Schedule 4.10	Administrative Actions
Schedule 4.13(a)	Benefit Plans
Schedule 4.13(f)	Payments Resulting from Transactions
Schedule 4.14(b)	Environmental
Schedule 4.17(c)	Commitments Since 12/31/97
Schedule 4.17(g)	Severance Payment
Schedule 4.20	Undisclosed Liabilities
Schedule 4.21	Insurance
Schedule 4.22	Year 2000 Compliance
Schedule 5.2	Commitments Prior to Closing
Schedule 5.5(a)	Severance Plan
Schedule 5.5(b)	Kodak Employee
Schedule 6.1(c)	Consents

EXHIBIT A Warrant Agreement

*Schedule
1.1(c)
IP*

NY12328:97443.11

-v-

REEL: 010797 FRAME: 0505

SCHEDULE I.1.c

MAY 05 2000

NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents
August 20, 1998

Title of Invention	Country	Patent/Appln. No.	Status
Aerosols Containing Bacteriostatic Nanoparticle Dispersions	U.S.	Patent No. 5,747,001	Granted
	Canada	Appln. No. 2,213,640	Pending
	Europe	Appln. No. 94504347.1	Pending
	Japan	Appln. No. 8-323798	Pending
Aerosols Containing Nanoparticle Dispersions	U.S.	Appln. No. 68/643,316	Pending
	Canada	Appln. No. 2,213,634	Pending
	Europe	Appln. No. 94504344.3	Pending
	Japan	Appln. No. 8-323798	Pending
Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors Using Cellulosic Surface Stabilizers and Methods of Making Such Formulations	U.S.	Appln. No. 68/690,402	Pending
	PCF	PCF/0898/14097	Pending
Pharmaceutical Compositions Containing Polyalkylene Block Copolymers Which Gel at Physiological Temperatures	U.S.	Patent No. 5,343,183	Granted
	U.S.	Patent No. 5,703,194	Granted
	Canada	Appln. No. 2,213,643	Pending
	Europe	Appln. No. 94507083.3	Pending
Nanoparticles Containing the R(-) Enantiomer of Ibuprofen	U.S.	Patent No. 5,718,919	Granted
	U.S.	Patent No. 5,585,108	Granted
Formulations of Oral Gastrointestinal Therapeutic Agents in Combination with Pharmacologically Acceptable Clays	U.S.	Patent No. 5,360,932	Granted
Microencapsulation of Nanoparticle Pharmacological Agents	U.S.	Patent No. 5,303,723	Granted
Isolation of Ultra Small Particles	U.S.	Patent No. 5,643,332	Granted
Nanoparticle Diagnostic Mixed Carbonic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging	U.S.	Patent No. 5,472,683	Granted
	U.S.	Patent No. 5,373,749	Granted
	U.S.	Patent No. 5,322,676	Granted
	U.S.	Patent No. 5,464,433	Granted
Iodinated Aryloxy Esters	U.S.	Patent No. 5,318,187	Granted
	U.S.	Patent No. 5,318,187	Granted
Method of Grinding Pharmaceutical Substances	Argentina	Appln. No. 326,306	Pending
	Australia	Patent No. 640832	Granted
	Canada	Appln. No. 2,187,400	Pending
	Taiwan	Patent No. NI-69476	Granted
	Czech Republic	Appln. No. 93/2277	Pending
	Europe	Appln. No. 93202793.6	Pending
	Finland	Patent/Appln. No. 934320	Pending

PATENT

REEL: 010797 FRAME: 0506

SCHEDULE 1.1.c

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents
August 20, 1998**

Title of Invention	Country	Patent/Appn. No.	Status
Method of Grinding Pharmaceutical Substances	Hungary	Patent No. 216031	Granted
	Japan	Appn. No. 282497/93	Pending
	South Korea	Appn. No. 22244/93	Pending
	Malaysia	Patent No. MY-109/1994	Granted
	Mexico	Appn. No. 93-6443	Pending
	New Zealand	Patent No. 241813	Granted
	Norway	Appn. No. 93-83719	Pending
	Philippines	Appn. No. 93/7839	Pending
	Russia	Patent/Appn. No. 93/32896	Pending
	Slovak Republic	Appn. No. PV 1301/93	Pending
	Ukraine	Appn. No. 93/3408	Pending
	Vietnam	Appn. No. 1484/93	Pending
	U.K.	Patent No. 2,573,783	Granted
Redispersible Nanoparticulate Film Matrices With Protective Overcoats	Canada	Appn. No. 2,212,803	Pending
	Europe	Appn. No. 94004412.7	Pending
	Japan	Appn. No. 8-325046	Pending
	U.K.	Patent No. 2,384,107	Granted
Isolated Aromatic Compounds	U.K.	Patent No. 2,382,401	Granted
Method to Reduce Particle Size Growth During Lyophilization	U.K.	Patent No. 2,382,401	Granted
Isolated Benzoyl Acetals and Ketals for X-Ray Imaging	U.K.	Patent No. 2,330,738	Granted
Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids	U.K.	Patent No. 2,571,556	Granted
	U.K.	Patent No. 2,360,331	Granted
	Canada	Appn. No. 2,207,304	Pending
	Europe	Appn. No. 93904332.3	Pending
	Japan	National Phase Appn. of PCT/US94/01433	Pending
Use of Non-Ionic Cloud Point Modifiers to Minimize Nanoparticle Aggregation During Sterilization	U.K.	Patent No. 2,346,782	Granted
The Use of Tylosin as a Nanoparticle Stabilizer and Dispersant	U.K.	Patent No. 2,429,124	Granted
	Argentina	Appn. No. 224,179	Pending
	Australia	Patent No. 643669	Granted
	Canada	Appn. No. 2,168,192	Pending
	Taiwan	Appn. No. 82108780	Pending
	Europe	Appn. No. 93283343.7	Pending
	Finland	Pat/Appn. No. 93/3383	Pending
	Hungary	Pat/Appn. No. 93/361394	Pending
	Israel	Appn. No. 93/107674	Pending
	Japan	Appn. No. 280794/93	Pending
	South Korea	Appn. No. 227609/93	Pending

SCHEDULE 1.1.e

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 28, 1998

Title of Invention	Country	Patent/Appln. No.	Status
The Use of Tylosin as a Nanoparticle Stabilizer and Dispersion	Malaysia	Appln. No. PI 9302634	Granted
	New Zealand	Patent No. 248726	Granted
	Norway	Appln. No. P934434	Pending
	Philippines	Patent No. 29937	Granted
	Russia	Appln. No. 93054941.00	Pending
	Slovak Republic	Appln. No. PV 1434-93	Pending
	Ukraine	Appln. No. 43003742	Pending
Iodinated Aryloxy Carbonamides	U.K.	Patent No. 2,360,478	Granted
	Argentina	Appln. No. 134,828	Pending
	Australia	Patent No. 642442	Granted
	Canada	Appln. No. 2,167,397	Pending
	Taiwan	Patent No. NI-872317	Granted
	Hungary	Pat/Appln. No. P9303473	Hungary
	Israel	Appln. No. 93/107884	Granted
	Japan	Appln. No. 240913003	Pending
	South Korea	Appln. No. 93/21134	Pending
	Malaysia	Patent No. MY-108,303A	Granted
	New Zealand	Patent No. 248431	Granted
	Philippines	Patent No. 30136	Granted
	Ukraine	Appln. No. 83/3409	Pending
	Venezuela	Patent No. 138493	Granted
X-Ray Contrast Compositions Useful in Medical Imaging	U.K.	Patent No. 2,431,393	Granted
	U.K.	Patent No. 2,318,767	Granted
	Europe	Appln. No. 92260132.4	Pending
Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization	U.K.	Patent No. 2,332,439	Granted
	Argentina	Appln. No. 154,325	Pending
	Taiwan	Appln. No. 83109723	Pending
	Japan	Appln. No. 244472/93	Pending
	South Korea	Appln. No. 93/21383	Pending
	Malaysia	Appln. No. PI 9303339	Pending
	Mexico	Appln. No. 937181	Pending
	New Zealand	Patent No. 230116	Granted
	Philippines	Appln. No. 47231	Pending
	Russia	Appln. No. 93/33883	Pending
	Slovak Republic	Appln. No. PV 1416/93	Pending
	U.K.	Appln. No. 08/600,006	Pending
Formulations of Nanoparticulate Naproxen Tablets	PCT	PCT/US98/03388	Pending

SCHEDULE 1.1.c

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 20, 1998			
Title of Invention	Country	Patent/Appln. No.	Status
Reduction of Intravenously Administered Nanoparticle Formulation Induced Adverse Physiological Reactions	U.S.	Appln. No. 08/694,754	Pending (Allowed)
	Canada	Based on PCT/US96/15300	Pending
	Europe	Based on PCT/US96/15300	Pending
	Japan	Based on PCT/US96/15300	Pending
Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles	U.S.	Patent No. 5,343,133	Granted
Surfactant-Block-Copolymer Coatings for Nanoparticle Compositions	U.S.	5,387,143	Granted
	Argentina	Appln. No. 132,333	Pending
	Australia	Appln. No. 2,834,683	Pending
	Canada	Appln. No. 2,181,303	Pending
	Taiwan	Appln. No. 8468107331	Pending
	Europe	Appln. No. 93923888.0	Pending
	Finland	Pat./Appln. No. 943234	Pending
	Israel	Patent/Appln. No. 94/114354	Pending
	Japan	Appln. No. 501303/94	Pending
	Malaysia	Appln. No. P19301774	Pending
	Norway	Appln. No. P 943433	Pending
	Philippines	Appln. No. 30809	Pending
	Venezuela	Appln. No. 93/1036	Pending
	U.S.	Appln. No. 08/491,339	Pending (Allowed)
	Argentina	Appln. No. 331,834	Pending
Method of Grinding Pharmaceutical Substances	Canada	Appln. No. 2,180,348	Pending
	Taiwan	Appln. No. 84104446	Pending
	Europe	Appln. No. 93919828.4	Pending
	Israel	Appln. No. 93/115832	Allowed
	Japan	Appln. No. 538332/93	Pending
	Malaysia	Appln. No. P19301374	Pending
	Philippines	Appln. No. 30573	Pending
	Venezuela	Appln. No. 0853-85	Pending
	U.S.	Patent No. 5,360,204	Granted
	U.S.	Patent No. 5,334,570	Granted
Method of Preparing Stable Drug Nanoparticles	U.S.	Patent No. 5,369,441	Granted
Sulfated Non-Ionic Block Copolymer Surfactant as Stabilizer Coatings for Nanoparticle Compositions	U.S.	Patent No. 5,244,610	Granted
Iodinated Aromatic Propagendioxanes	U.S.	Patent No. 5,322,404	Granted
Iodinated Aryloxy Ketones	U.S.	Patent No. 5,418,133	Granted

SCHEDULE 1.1.e

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 20, 1998

Title of Invention	Country	Patent/Appln. No.	Status
General Purpose Diagnostic/Therapeutic Agent Containing a Tri-Iodinated Benzoyl Group Attached to a Cocaine	U.S.	Patent No. 5,643,330	Granted
Improved Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents and Oral Gastrointestinal Therapeutic Agents	U.S.	Patent No. 5,621,981	Granted
Nanoparticles in Iodipamide Derivatives for Use as X-Ray Contrast Agents	U.S.	Appln. No. 08/813,348	Pending
Nanoparticles Diagnostic Diagnostic X-Ray Contrast Agents for Blood Pool and Therapeutic System Imaging	U.S.	Patent No. 5,531,318	Granted
Barium Salt Formulations Stabilized by Poly-ionic and Anionic Stabilizers	U.S.	Patent No. 5,393,637	Granted
Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents	U.S.	Patent No. 5,481,492	Granted
Novel Formulations for Nanoparticle X- Ray Blood Pool Contrast Agents Using High Molecular Weight Non-Ionic Surfactants	U.S.	Patent No. 5,336,352	Granted
Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Formulation	U.S.	Patent No. 5,447,710	Granted
Use of Charged Phospholipids to Reduce Particle Aggregation	U.S.	Patent No. 5,398,362	Granted
Process of Preparing Therapeutic Compositions Containing Nanoparticles	U.S.	Patent No. 5,310,118	Granted
Nanoparticle NSAID Formulations	U.S.	Patent No. 5,518,758	Granted
	Canada	Appln. No. 2,312,779	Pending
	Europe	Appln. No. 9803181.2 (to be completed in all EP designated countries)	Pending (Allowed)
	Japan	Appln. No. 8-324248	Pending
Microprecipitation of Nanoparticles Pharmaceutical Agents	U.S.	Patent No. 5,380,932	Granted
Microprecipitation of Nanoparticles Pharmaceutical Agents Using Surface Active Material Derived From Similar Pharmaceutical Agents	U.S.	Patent No. 5,716,642	Granted
Co-Microprecipitation of Nanoparticles Pharmaceutical Agents with Crystal Growth Modifiers	U.S.	Patent No. 5,643,331	Granted
Co-Microprecipitation of Nanoparticles Pharmaceutical Agents with Crystal Growth Modifiers	U.S.	Patent No. 5,642,893	Granted
Surface Modified Drug Nanoparticles	U.S.	Patent No. 5,143,684	Granted
	Argentina	Appln. No. 92/321681	Pending

SCHEDULE 1.1.c

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 30, 1998			
Title of Invention	Country	Patent/Appln. No.	Status
Surface Modified Drug Nanoparticles	Australia	Patent No. 634836	Granted
	Canada	Appln. No. 2858433	Pending
	Chile	Appln. No. 92074	Pending
	Columbia	Patent No. 24833	Granted
	Europe	Appln. No. 92308133.2 Publication No. 496299	Pending
	Finland	Pat/Appln. No. 920371	Pending
	Hungary	Pat/Appln. No. 92-238	Pending
	Ireland	Appln. No. 92-0217	Pending
	Israel	Patent/Appln. No. 160754	Granted
	Japan	Appln. No. 92/11228	Pending
	South Korea	Appln. No. 92/1677	Pending
	Malaysia	Patent No. MY-108134-A	Granted
	Mexico	Patent No. 178345	Granted
	New Zealand	Patent No. 241362	Granted
	Norway	Appln. No. 92-00334	Allowed
	Philippines	Patent No. 29069	Granted
	Russia	Pat. No. 2084333	Granted
	Singapore	Appln. No. 9604361-3	Pending
	Taiwan	Patent No. NJ-071312	Granted
Surface Modified Anticancer Nanoparticles	U.S.	Patent No. 5,494,683	Granted
	U.S.	Patent No. 5,398,363	Granted
	Argentina	Appln. No. 92/313,230	Pending
	Australia	Patent No. 673432	Granted
	Canada	Appln. No. 2858342	Pending
	Czech Republic	Appln. No. PV 131693	Pending
	China	Appln. No. 93108050.9	Pending
	Europe	Appln. No. 93201883.1 Publication No. 577215	Pending
	Finland	Pat/Appln. No. 933040	Pending
	Hungary	Pat/Appln. No. 93301917	Pending
	Israel	Patent/Appln. No. 106198	Pending
	Japan	Appln. No. 93/138808	Pending
	South Korea	Appln. No. 92/12287	Pending
	Malaysia	Appln. No. PI 9301273	Pending (allowed)
	Mexico	Appln. No. 933930	Pending
	New Zealand	Patent No. 248042	Granted
	Norway	Appln. No. 93-2403	Pending
	Philippines	Patent No. 30104	Granted
	Russia	Appln. No. 93046236	Pending
	Singapore	Appln. No. 9605605-6	Pending
	Slovak Republic	Pat/Appln. No. PV 0681-93	Pending
	Taiwan	Patent No. NJ-679296	Granted
	Ukraine	Appln. No. 93003037	Pending

Issued and Granted Patents

August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Surface Modified Anticancer Nanoparticles	Venezuela	Pat/Appn. No. 0849-83	Pending
Surface Modified NEAD Nanoparticles	U.K.	Patent No. 3,332,160	Granted
	Australia	Patent No. 677/83	Granted
	Austria	European Patent No. 644 733	National Registration of EP 644 733
	Belgium	European Patent No. 644 733	National Registration of EP 644 733
	Canada	Appn. No. 2118317	Pending
	Denmark	European Patent No. 644 733	National Registration of EP 644 733
	Europe	European Patent No. 644 733	Granted
	France	European Patent No. 644 733	National Registration of EP 644 733
	Germany	European Patent No. 644 733	National Registration of EP 644 733
	Greece	European Patent No. 644 733	National Registration of EP 644 733
	Hungary	Pat/Appn. No. 84-3343	Pending
	Ireland	European Patent No. 644 733 Irish Patent No. 1172603	Granted
	Italy	European Patent No. 644 733	National Registration of EP 644 733
	Japan	Appn. No. 50/501313	Pending
	Luxembourg	European Patent No. 644 733	National Registration of EP 644 733
	Monaco	European Patent No. 644 733	National Registration of EP 644 733
	Mexico	Appn. No. 83-3332	Pending
	Netherlands	European Patent No. 644 733	National Registration of EP 644 733
	Portugal	European Patent No. 644 733	National Registration of EP 644 733
	Spain	European Patent No. 644 733	National Registration of EP 644 733

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents
August 20, 1998**

Title of Invention	Country	Patent/Appln. No.	Status
Modified NSAID Nanoparticles	Sweden	European Patent No. 644 755	National Registration of EP 644 755
	Switzerland	European Patent No. 644 755	Granted
	United Kingdom	European Patent No. 644 755	National Registration of EP 644 755
Controlled Adhesion Within the GI-Tract Nanoparticles Stabilized by High Molecular Weight, Linear Poly(ethylene oxide) Polymers	U.S.	Patent No. 5,585,379	Granted
Imaging X-Ray Contrast Agents	U.S.	Patent No. 5,575,730	Granted
Emulsified Surfactant for Nanocrystals	U.S.	Patent No. 5,525,938	Granted
Emulsions of Oral Gastrointestinal Contrast X-Ray Contrast Agents in Emulsion with Pharmaceutically Acceptable Clays	U.S.	Patent No. 5,466,440	Granted
Novel Naproxen with Hydroxypropyl Cellulose as a Dispersion Stabilizer	U.S.	Patent No. 5,391,436	Granted
Novel Triodo-3-Substituted-Amino- Phthalate Esters Useful as X-Ray Contrast Agents for Medical Diagnostic Imaging	U.S.	Patent No. 5,670,136	Granted
Novel (Amino) Amino-3,4,5- Triiodophenyl Esters	U.S.	Patent No. 5,665,916	Granted
Novel Method of Grinding Pharmaceutical Substances	U.S.	Patent No. 5,718,388	Granted
	Argentina	Appln. No. 331,937	Pending
	Canada	Appln. No. 2,190,134	Pending
	Taiwan	Appln. No. 84163643	Pending
	Europe	Appln. No. 93919082.6	Pending
	Israel	Appln. No. 113851	Pending
	Japan	Appln. No. 95/538177	Pending
	Malaysia	Appln. No. P1 9501375	Pending
	Philippines	Appln. No. 95/50574	Pending
	Venezuela	Appln. No. 0834-95	Pending
Alkylphenyl Esters as Novel X-Ray Contrast Agents	U.S.	Appln. No. 08/677,708	Pending
Novel 3-Amino-3-Iodophenyl Esters as X- Ray Contrast Agents	U.S.	Patent No. 5,681,186	Granted September 16, 1997
Novel Copolymers and a Process for Preparing Them	U.S.	Appln. No. 08/656,810	Pending
	Argentina	Appln. No. 331,135	Pending
	Canada	Appln. No. 2,287,589	Pending
	Taiwan	Appln. No. 8466162792	Pending
	Europe	Appln. No. 93904326.4	Pending
	Israel	Appln. No. 940112136	Pending

SCHEDULE 1.1.c

**NanoSystems Intellectual Property Portfolio of
Pending and Granted Patents
August 10, 1998**

Title of Invention	Country	Patent/Appln. No.	Status
Copolymer and a Process for Making Them	Europe	National Phase of PCT/EP94/04261	Pending
	Japan	National Phase of PCT/JP94/04261	Pending
	Malaysia	Appln. No. PI 930832	Pending
	Mexico	Appln. No. 931133	Pending
	Philippines	Appln. No. 90838	Pending
	Greece	Patent No. 228377	Granted
	Britain		
Rhombohedral Crystalline Form of Triamcinolone Acetonide, Compositions Containing the Rhombohedral Crystalline Form of Triamcinolone Acetonide, Methods of Making and Using Such Compositions, and Methods of Making Nanocrystalline Compositions of Tetragonal Crystalline Form of Triamcinolone Acetonide Stable Formulations of Naproxen	Venezuela	Appln. No. 930324	Pending
	U.S.	Appln. No. 08/961,211	Pending
	U.S.	Appln. No. Unknown (filed on August 13, 1998)	Pending

the Acquired Assets are subject, other than in the case of clauses (ii) and (iii) any conflict, breach, default, termination, cancellation, acceleration, loss, violation or Encumbrance which, individually or in the aggregate, would not have a Material Adverse Effect or materially impair or delay Seller's ability to perform its obligations hereunder.

4.4 Binding Effect. This Agreement constitutes a valid and legally binding obligation of Seller enforceable in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors' rights and to general equity principles.

4.5 Consents and Approvals. Except as required by the H-S-R Act, no consent, approval, waiver or authorization is required to be obtained by Seller from, and no notice or filing is required to be given by Seller to or made by Seller with, any Federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by Seller of this Agreement other than those the failure of which to obtain, give or make would not have a Material Adverse Effect or materially impair or delay the ability of Seller to effect the Closing.

4.6 Intellectual Property. To the best Knowledge of Seller, Seller owns or has the right to use all of the Intellectual Property included in the Acquired Assets. The Intellectual Property included in the Acquired Assets constitutes all of the Intellectual Property necessary to conduct the Business as currently conducted. Schedule 1.1(c) contains a worldwide list of all patents, trade names, trademarks and service marks, and applications for the foregoing owned or possessed by the Seller and true and complete copies of all such materials have been made available to Buyer. Seller has taken all action reasonably necessary to establish and protect its interest in and to the NanoSystems Intellectual Property. To the Knowledge of Seller, (i) Seller's products do not infringe on or otherwise violate the Intellectual Property of any other Person, and (ii) no Person is challenging, infringing or otherwise violating the NanoSystems Intellectual Property. Except as set forth in the Contracts listed on Schedule 4.6(b), there is no limitation on Seller's ability or right to license any of the NanoSystems Intellectual

NY12528: 97445.11

-17-

Property to any Person. All issued patents and registered trademarks and service marks owned by Seller are recorded on the public record solely in the name of Seller.

4.7 Title to and Condition of Tangible Property. Seller has good title to, or a valid and binding leasehold interest in, the tangible property included in the Acquired Assets, free and clear of all Encumbrances, except (i) liens for Taxes, assessments and other governmental charges (a) not yet due and payable or (b) being contested in good faith by appropriate proceedings and for which adequate reserves have been established, and (ii) Encumbrances which, individually or in the aggregate, would not have a Material Adverse Effect. Upon the consummation of the transactions contemplated hereby, assuming Buyer is a bona fide purchaser for value with no knowledge of an adverse claim, Buyer will acquire good title to the tangible property included in the Acquired Assets, free and clear of all Encumbrances, except for the exceptions in clauses (i) and (ii) of this Section 4.7. The tangible property included in the Acquired Assets is in all material respects in good working condition, ordinary wear and tear excepted.

4.8 Contracts.

(a) Schedule 4.8(a) sets forth a list, as of the date hereof, of each Contract that is material to Seller. Each such Contract is a valid and binding agreement of Seller or its Affiliates and is in full force and effect.

(b) To the Knowledge of Seller, there has been no material breach or default under any Contract listed on Schedule 4.8(a) except for defaults that have been cured or waived and breaches and defaults which are not material. No event has occurred with respect to Seller which, with notice or lapse of time or both, would constitute a material breach, violation or default, or give rise to a right of termination, cancellation, foreclosure, imposition of a lien or penalty, prepayment or acceleration under any such Contract.

(c) Seller is not a party to any Contract in any of the following categories:

NY12328: 97443 11

-18-

ASSIGNMENT OF INTELLECTUAL PROPERTY OTHER THAN PATENT

KNOW ALL PERSONS BY THESE PRESENTS that in connection with the Asset Purchase Agreement, dated as of August 21, 1998 (the "Agreement"), by and among Elan Corporation, plc, a public limited company organized under the laws of Ireland ("Buyer"), NanoSystems L.L.C., a limited liability company organized under the laws of the State of Delaware ("Seller"), and Eastman Kodak Company, a New Jersey corporation (capitalized terms not defined herein shall have the meaning ascribed to them in the Agreement), Seller, for good and valuable consideration, receipt of which is hereby acknowledged, hereby ASSIGNS to Buyer all of Seller's right, title and interest in and to all Intellectual Property included in the Acquired Assets (other than the rights to develop and commercialize a nanocrystal version of Paclitaxel) in accordance with the terms of the Agreement.

IN WITNESS WHEREOF, Seller has caused this instrument to be executed by its duly authorized officer on the 1st day of October, 1998.

NANOSYSTEMS L.L.C.

By: Particulate Prospects Corp.,
Member

By: M. Sandhu
Name: Akram Sandhu
Title: Vice President

NY12525-1998203

Received: 04-22-99 11:08am
RECORDED: 05/05/2000

From-

To-FOLEY AND LARDNER Page 05
PATENT
REEL: 010797 FRAME: 0517